On February 12, 2026 during the “Conversion Conclave” in Chennai, Bharat Biotech Executive Chairman Dr. Krishna Ella announced a significant long-term expansion into Tamil Nadu. The company has signed a Memorandum of Understanding (MoU) with the state government to invest ₹5,000 crore in a new biosciences and medicine manufacturing park in Kancheepuram district.
This facility marks a strategic pivot for Bharat Biotech, moving beyond its core vaccine legacy (like Covaxin) toward high-tech biologics and chronic disease management.
Project Blueprint: AI-Guided Biologics
Unlike its plants in Hyderabad and Odisha, the Kancheepuram facility will focus on the next frontier of medicine:
- Therapeutic Focus: Specifically targeting Diabetes and other non-communicable diseases.
- Key Products: Production of monoclonal antibodies and innovative “AI-guided” biologics.
- The AI Edge: Dr. Ella highlighted that the facility will tap into advances in AI-guided biologics design to develop innovative therapeutic approaches rather than duplicating existing vaccine or food production lines.
- Timeline: While the MoU has been signed, Dr. Ella categorized this as a long-term initiative, emphasizing that while R&D may occur across their global sites, the Chennai-area plant will be a primary production hub.
Strategic Rationale & State Efficiency
Dr. Ella admitted to initial skepticism about Tamil Nadu’s industrial agility but was “impressed” by the state’s performance:
- Speed of Execution: The state government converted the initial outreach into a formal MoU within 45 days, with minimal direct meetings required.
- Job Creation: The project is expected to create 5,000 direct jobs, contributing to the state’s goal of distributed industrial growth.
- The “Dravidian Model”: Chief Minister M.K. Stalin used the Bharat Biotech MoU as a prime example of the state’s high conversion rate (73.53%) of investment agreements into real-world projects.
Industry Context: Biopharma SHAKTI
The announcement coincides with the Union Budget 2026–27 proposal for “Biopharma SHAKTI,” a ₹10,000 crore national initiative to strengthen India’s end-to-end ecosystem for biologics and biosimilars. Bharat Biotech’s investment positions Kancheepuram as a key node in this national mission to reduce import dependence on high-value medicines.
“We do not want to duplicate vaccines here. I am focusing on how to bring innovative biologics through AI… The Chennai facility will be where we make these products a reality.” — Dr. Krishna Ella, Executive Chairman, Bharat Biotech.